Procter & Gamble Health Ltd - 500126 - Corporate Action-Board approves Dividend
We inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended a final dividend of Rs. 130 per equity share, for the financial year ended June 30, 2021, which includes a one-time special dividend of Rs. 90 per equity share. Kindly take the same on record. Procter & Gamble Health Ltd - 500126 - Outcome Of The Board Meeting Held On August 26, 2021
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Audited Financial Results for Financial Year ended June 30, 2021 were approved. We are enclosing herewith the following: Audited Financial Results for the Financial Year ended June 30, 2021, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015; Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company; Press Release; and A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results We further inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended a final dividend of Rs. 130 per equity share, for the financial year ended June 30, 2021, which includes a one-time special dividend of Rs. 90 per equity share. Procter & Gamble Health Ltd - 500126 - Board Meeting Outcome for Outcome Of The Board Meeting Held On August 26, 2021
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Audited Financial Results for Financial Year ended June 30, 2021 were approved. We are enclosing herewith the following: Audited Financial Results for the Financial Year ended June 30, 2021, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015; Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company; Press Release; and A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results We further inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended a final dividend of Rs. 130 per equity share, for the financial year ended June 30, 2021, which includes a one-time special dividend of Rs. 90 per equity share. Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015,we hereby inform you regarding issue of duplicate share certificate(s) to the shareholder(s) of the Company, on August 18,2021.
Berkshire Hathaway cuts stake in drug companies, sheds Axalta, Biogen
In the second quarter, Berkshire said it exited a $180 million stake in Biogen Inc and reduced investments in Abbvie Inc, Bristol-Myers Squibb Co and Merck Procter & Gamble Health Ltd - 500126 - Board Meeting Intimation for Consideration And Approval Of Audited Financial Results And Statements For The Financial Year Ended June 30, 2021 And Recommendation Of Dividend (If Any).
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/08/2021 ,inter alia, to consider and approve We would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, August 26,2021, inter alia, to consider and approve Audited Financial Results and Statements for the Financial Year ended June 30, 2021 and to consider recommendation of dividend (if any). Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015,we hereby inform you regarding issue of duplicate share certificate(s) to the shareholder(s) of the Company on August 06,2021. We request you to take the same on record and acknowledge the receipt. Procter & Gamble Health Ltd - 500126 - Disclosure: SEBI Circular No SEBI/HO/DDHS/CIR/P/2018/144 Dated November 26, 2018 With Respect To Disclosure Of Fund Raising By Issuance Of Debt Securities By Large Entities.
We refer to the SEBI Circular No SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 with respect to fund raising by issuance of Debt Securities by large entities and disclosures thereof by such large entities. In this regard, we wish to inform you that the Company does not fall under the criteria as specified in para 2.2 of the said SEBI Circular. Hence, our Company does not classify as a 'Large Corporate' under the framework provided in the above-mentioned circular for the financial year 2020-21. Procter & Gamble Health Ltd - 500126 - Certificate Under Regulation 40(9) Of The SEBI Listing Regulations.
With reference to the above we are enclosing herewith Certificate under Regulation 40(9) of the SEBI Listing Regulations for the year ended June 30, 2021. Procter & Gamble Health Ltd - 500126 - Shareholding for the Period Ended June 30, 2021
Procter & Gamble Health Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here